Strategic divestment Bayer recently sold assets including the oral contraceptive Meliane rights in 30 markets, indicating active portfolio optimization and openness to external partnerships or licensing opportunities for related consumer health and contraception solutions.

Digital tools Launch of digital pest monitoring tool MagicTrap 2 and involvement in digital health/operational tech signals openness to SaaS or data-enabled solutions, including IoT, analytics platforms, and digital workflow enhancements for pharma operations.

Manufacturing excellence Award-winning SOLIDA-1 facility and strong focus on manufacturing in Leverkusen present opportunities for university-industry collaborations, process optimization contracts, and supply chain consulting or automation services.

Partnered trials Active collaboration with Kairos Pharma to evaluate antibody candidates combined with existing Bayer therapies suggests continued appetite for strategic research partnerships, co-development deals, and access to clinical-grade bioanalytics services.

Cost and headcount dynamics Significant workforce reductions indicate potential for cost optimization services, organizational efficiency solutions, and targeted talent or vendor management offerings to align with Bayer’s restructuring and efficiency drives.